At My Intelligent Machines, we are helping life scientists harness the power of human and artificial intelligence to push the boundaries of drug development.
Seventy percent of phase II and III clinical trials fail because patients with the same disease respond differently to treatments. This costs the biopharma industry more than $20B in losses annually. The cost of human life is even greater.
MIMs is a software-as-a-service (SaaS) company with an augmented-intelligence platform leveraging systems biology, distributed computing, and machine learning to unleash the power of reverse translational research. We are changing the research paradigm for endotype characterization, target and indication prioritization, and target and biomarker discovery, in oncology, immune-related disorders, infectious diseases, and more.
MIMs’ transformational software solutions are made possible by an inclusive team of remarkable and diverse humans – leaders of today and tomorrow in their respective fields. Together, we have brought a machine to life. Our love of science knows no bounds. Our plans are daring. Our future goals are lofty.
Sound too good to be true? It isn’t.
We are My Intelligent Machines Inc.